Physician profile
Ran Choi
NPI 1053652115
$1,517.19
in general payments reported to CMS, 2019-2025
14 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $409 · 2023: $63.52 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.66 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.69 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Janssen Biotech, INC. | $108.27 | 2021 | |
| Celgene Corporation | $89.43 | 2022 | |
| Ardelyx, INC. | $75.18 | 2022-2023 | Ibsrela |
| Amgen INC. | $65.69 | 2021 | |
| Vyne Pharmaceuticals INC. | $60.33 | 2021 | |
| Braintree Laboratories, INC. | $52.38 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $45.26 | 2021 | |
| Ironwood Pharmaceuticals, INC | $24.43 | 2021 | |
| Gilead Sciences, INC. | $19.61 | 2021 | |
| Biofrontera INC. | $17.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ran Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.